Botanic Healthcare has published new human clinical data demonstrating the superior bioavailability of Lipomac, its clinically engineered liposomal vitamin C, developed using proprietary DFS Technology.
The study provides direct pharmacokinetic evidence that Lipomac delivers significantly higher systemic exposure than conventional vitamin C formulations.
The study was conducted as a randomized, open-label, crossover trial in 12 healthy adult subjects.
Participants received:
Pharmacokinetic parameters were then directly compared within the same subjects.
The results showed clear advantages for Lipomac:
These findings confirm that Lipomac overcomes the absorption ceiling commonly associated with conventional vitamin C.
Traditional vitamin C is highly vulnerable to:
Liposomal delivery addresses these challenges by:
The study offers human clinical validation of liposomal technology as a scalable nutraceutical delivery platform.
Lipomac is developed using Botanic Healthcare’s patented DFS Technology, designed to:
Lipomac is part of Lipsobio, Botanic Healthcare’s advanced liposomal ingredient portfolio, which spans:
Each ingredient is authenticated using:
“These findings validate the core scientific engineering behind DFS Technology,” said Dr. H. N. Shivaprasad, Chief Scientific Officer at Botanic Healthcare. “They reinforce the measurable performance advantages of liposomal formats.”
The publication further strengthens Botanic Healthcare’s evidence-backed ingredient portfolio and highlights its commitment to translating advanced delivery science into clinically meaningful health solutions for global partners.